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Abstract
Obesity and headache are two highly prevalent diseases both in adults and children and they are associated with
a strong personal and social impact. Many studies suggest that obesity is comorbid with headache in general, and
migraine in particular and obesity seems to be a risk factor for migraine progression and for migraine frequency
both in adults and in children. Research shows that there are multiple areas of overlap between migraine pathophysiology
and the central and peripheral pathways regulating feeding: inflammatory mediators such as the calcitonin gene-related
protein (CGRP), neurotransmitters such as serotonin, peptides such as orexin and adipocytokines such as adiponectin (ADP)
and leptin could explain the common pathogenesis. In this paper we discussed the association between obesity
and migraine through the analysis of the most recent studies in children and we reviewed data from literature in
order to assess the association between obesity and headache and to clarify the possible common pathogenic
mechanisms.
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Background
Obesity and headache are two common diseases in
adults and children and many data suggest their fre-
quent association [1]. Both are influenced by genetic and
environmental risk factors and are related with an
increased risk of developing chronic diseases with a
marked personally impact and high healthcare costs [2].
Type 2 diabetes mellitus, dyslipidemia, metabolic syn-
drome, hyperandrogenemia with hyperinsulinemia and
consequent polycystic ovary disease, high systolic blood
pressure, proteinuria, nonalcoholic fatty liver disease,
orthopedic pathologies, pseudotumor cerebri and
depression are just some of the conditions associated
with obesity [3]. In addition, recent researches suggest a
role of obesity on migraine outcomes [1, 4]. In fact, the
link between obesity and headache seems to be relatively
specific only for migraine [5] and studies in adults and
children showed that obesity is a risk factor for migraine
progression and for migraine frequency both in adults
[6–9] and in children [10–12]. The link between
migraine and obesity is multifactorial: inflammatory
mediators such as the calcitonin gene-related protein
(CGRP), neurotransmitters such as serotonin, peptides
such as orexin, and adipocytokines such as adiponectin
and leptin play a role both in feeding and migraine
physiopathology and could explain the common patho-
genesis [13].
Furthermore, a decrease in body weight may lead to a
reduction in the incidence and severity of headache and
my also represent an important therapeutic strategy [14].
The aim of this review is to discuss the association
between obesity and migraine through the analysis of
the most recent studies in children and to explore the
potential role of weight-loss in the treatment of
migraine.
Obesity: definition and prevalence
World Health Organization defines obesity and over-
weight as clinical conditions characterized by excessive
body weight and associated with increased mortality and
morbidity. Body mass index (BMI) is the ratio between
body weight (in kg) and height (in m2) and is universally
used to define the degree of obesity. For adults, a BMI
of 25.0 to 29.9 kg/m2 is defined as overweight and a
BMI of 30 kg/m2 or higher is defined as obese [15].
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For children and adolescents two worldwide BMI
criteria are used: the International Obesity Task Force
(IOTF) cutoffs and the World Health Organization
(WHO) cutoffs. The WHO system was created using
data from the 1997 National Center for Health Statistics
(NCHS) (from 1 to 24 years) and defines obesity as a
BMI >2 SD from the mean of the WHO reference popu-
lation for children aged between 5 and 19 years. For
children under 5 years, WHO defines obesity as a
weight-for-height greater than three standard deviations
above the WHO Child Growth Standards median [16].
The IOTF cutoffs are based on six large international
sample from Brazil, China, United States, Great Britain,
Holland, and Singapore and are an extrapolation of the
adult BMI cutoff points for obesity (30 kg/m2) [17].
Because pediatric cutoffs vary by age, sex and racial
differences in adipose tissue, values of BMI are reported
on percentiles tables, that are different, depending on
the country. Specifically, according to Italian charts,
overweight is defined as a BMI ≥85th percentile for sex
and age, and obesity is defined as a BMI ≥95th percentile
for sex and age [18].
BMI is an indicator related to total individual mass,
but it is well recognized that fat mass, expecially
abdominal fat mass, is more strictly associated with an
increased risk of several pathological states; so, obesity
should be most accurately estimated by demonstration
of an increase in abdominal fat mass using direct mea-
surements with CT or MRI imaging, or indirect indexes
such as waist circumference and bio-impedance. [19].
However direct measurements are not practical in rou-
tine and are too much expensive; among indirect mea-
surements, waist circumference is frequently used in
diagnosis of abdominal obesity in pediatric population
by reporting the values as percentile calculated on tables
representing normal values for age, sex and height [20].
Obesity has reached epidemic proportions representing
a really social and health emergency. The prevalence of
overweight and obesity is steadily increasing among ado-
lescents and children and it is estimated that approxi-
mately 41 million children under the age of five are
overweight or obese In addition, about 2–8% of the overall
costs for health is linked to obesity and the size of the
problem in the USA is double compared to Europe,
although the rate of increase in European countries is
highest [15].
Migraine: definition and prevalence
The International Headache Society defines migraine as
a primary headache disorder characterized by recurrent
headaches that can occur with or without aura. Migraine
with aura is characterized by transient focal neurological
symptoms that usually precede or sometimes join with the
headache. In addition, migraine generally lasts 4–72 h and
it can be also associated with a premonitory phase,
occurring hours or days before the headache, and with
a headache resolution phase. Importantly, the diagnostic
criteria used in children are less restrictive than those used
in adults: attacks may last 2–72 h and migraine is more
often bilateral than in adults; unilateral pain usually
emerges in late adolescence and migraine headache is
usually frontotemporal [21].
As obesity, headache is very common in childhood. In
children under 10 years old, headache prevalence has
been reported to be approximately 56% [22] and data
suggest that from adolescence to early adulthood the
prevalence of headache increases and girls have 53%
higher odds of headache than boys [23].
Migraine and obesity: pathophysiological
mechanisms
A direct association between obesity and migraine has
not been completely understood but it is likely to be
multifactorial, related on both central and peripheral
pathways regulating feeding and adipose tissue function,
that overlap with pathways implicated in migraine
pathophysiology [24], as well as lifestyle and environ-
mental factors [25].
Regulation of feeding is controlled by various brain
regions, in particular by hypothalamus and its connec-
tions, the so-called melanocortin system. The arcuate
nucleus (ARC) releases orexigenic and anorexigenic
neuropeptides that trasmitte to paraventricular nucleus
(PVN), ventromedial nucleus (VM) and lateral hypo-
thalamus (LH). From LH, other two groups of neurons
(orexin neurons, which stimulate feeding, and melanin-
concentrating hormone neurons, which inhibit feeding),
project to the brainstem nuclei (the nucleus of the tractus
solitarius and the dorsomotor nucleus of the vagus) where
descending inputs are integrated with peripheral inputs
from the gastrointestinal system [26]. Hypothalamus plays
a crucial role in migrain pathogenesis too: this is suggested
by the presence in migraineurs of predromal and post-
dromal hypothalamic signs, such as food cravings,
mood and sleep disorders [27] and confirmed by the
finding of hypothalamic activation during acute migraine
attacks [28]. Various neurotransmitters and peptides
directed by the hypothalamus in regulation of feeding
control have also a role in migraine pathophysiology:
– Serotonin is a neurotransmitter synthesized from the
essential aminoacid tryptophan. At the hypothalamic
level serotonin directly activate anorexigenic
neurons and cause the release of α-melanocyte-
stimulating hormone; serotonin is also linked to
other hypothalamic peptides involved in feeding
control as Neuropeptide-Y and Orexin [29]. Serotonin
is a major player in the process of feeding control,
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signaling the satiety state. This is supported by the
finding that serotonin agonist drugs markedly reduce
appetite and lead to weight loss. Furthermore, several
studies have noted chronically low interictal levels of
serotonin in migraineurs [30] and increased levels
during acute attacks [31]. Probably serotonin deficit in
migraineurs could also explain tendency for increased
appetite [32].
– Orexines are hypothalamic peptides involved in
several functions including feeding, sleep and
hormone secretion, and even in modulation of
nociceptive processing [33]. Specifically, Orexin A
and Orexin B are secreted by hypothalamic neuronal
cells and modulate feeding control: administered
centrally in rats they increase food intake [34–36];
orexin A levels seems to be elevated in the
cerebrospinal fluid of migraine patients and in
chronic daily headache sufferers, probably due to
orexin resistance or disruption in orexin receptors
[37] and animal and human data support a role for
orexins in pain processing [38]. In an animal model,
orexin A inhibits neurogenic dural vasodilatation
and reduces release of calcitonin gene related
peptide (CGRP) from trigeminal neurons [39].
– CGRP is a 37 amino acid neuropeptide which plays
an important role in migraine: this is assessed by
several studies that found elevated values in the
jugular outflow during migraine attacks and
normalized values parallel to pain resolution [40, 41].
In another study is demonstrated that CGRP injected
intravenously caused a delayed moderate or severe
headache in migraine patients but not in non-
migraineurs [42]. This evidence supports the
hypothesis of CGRP being important in the induction
as well as in the perpetuation of the migraine attack:
migraineurs may have an increased sensitivity to
CGRP due to differences in expression of the
functional rate limiting subunit of the CGRP receptor
[43]. On the other hand there is strong evidence
suggesting that CGRP has immunomodulatory
effects and it shows potent anti-inflammatory effects
in several animal models of inflammation [44] and in
humans, CGRP has been reported elevated in
conditions where inflammation is implicated [45].
Since obesity is related to a chronic inflammation
too, it is plausible that chronically elevated circulating
levels of CGRP, or increased sensitivity to otherwise
normal levels of CGRP, may decrease the
trigeminovascular activation threshold and increase
or trigger frequency of migraine attacks [46].
In addition to peptides and neurotransmitters, adipo-
cytokines participate in energy homeostasis and regula-
tion of feeding; some of them, such as ADP and leptin,
play a central role even in immune and inflammatory
process and are produced by adipose tissue [24].
Adipose tissue produces both pro and anti-inflammatory
mediators that influence local and systemic inflammation
[47, 48]. The balance of pro- and anti-inflammatory adipo-
kines is dictated by different factors including nutritional
and metabolic status, presence of infection or systemic
inflammation, oxidative stress, age and sex [49, 50].
The expansion of subcutaneous adipose tissue hyper-
plasia mediated is associated with a lower risk of meta-
bolic disease, higher levels of ADP, and lower levels of
proinflammatory adipokines. In contrast, the expansion
of adipose tissue through the process of hypertrophy is
prevalent in visceral adipose tissue and is highly corre-
lated with the accumulation of immune cells, proinflam-
matory adipokines, and metabolic dysfunction [51, 52].
These molecules are involved in the pathogenesis of
migraine too:
– ADP is predominantly produced by adipocytes and
is present in the blood circulation as total ADP and
includes three multimers: heavy molecular weight
(HMW-ADP), middle molecular weight (MMW-
ADP) and low molecular weight (LMW-ADP) [53].
ADP and its multimers have both pro- and anti-
inflammatory effects: HMW-ADP can activate
proinflammatory pattern and is associated with
increases in interleukin (IL)-6 levels, whereas LMW-
ADP show an anti-inflammatory activity by reducing
IL-6 levels [7]. ADP and its multimers correlate with
obesity status, showing inverse correlation with
BMI, with insulin sensitivity and serum lipids [54]
and are present in cerebrospinal fluid in lower
concentration than in blood [55]. In the brain, ADP
receptors are expressed in the cortex, hypothalamus,
brainstem, circumventricular organs, and on the
endothelium of the cerebral microvasculature. ADP
signaling is mediated by multiple pathways including
some implicated in migraine such as nuclear factor
kappa beta, AMP-activated protein kinase, and
others [56, 57].
Several studies report increased total ADP levels in
migraine subjects compared to controls, after
adjusting for waist/hip ratio or BMI [58, 59], and
elevated proinflammatory oligomers directly
associated with migraine severity; however substantial
methodological differences limit firm conclusions,
even considering related metabolic factors that may
act as mediators or confounders [60].
– Leptin is another adipokine producted by adipose
tissue and present in the brain. It is associated with
satiety and obese individuals exhibit high circulating
levels, suggesting leptin resistance in obesity [61].
Furthermore, leptin is implicated in the modulation
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of inflammation and pain, but studies evaluating
interictal leptin levels in migraineurs are
inconclusive, reporting low or elevated or equal
levels in migraineurs compared to controls [62].
Two studies evaluating ictal leptin levels in adults
and in a pediatric population, reveal the possibility
that leptin may be inversely associated with pain
severity, with decreased levels during active pain and
increased levels interictally [63, 64].
In addition to adipokines, several cytokines have been
described in migraineurs: Tumor Necrosis Factor α
(TNFα) and IL-6 are increased in ictally episodes of
patients with migraine and TNFα is increased in cere-
brospinal fluid of chronic daily headache sufferers [65];
furthermore, ADP and leptin have reciprocal relation-
ships with several of these cytokines, suggesting a
possible integration of multiple patterns implicated in
migraine attacks pathogenesis.
Pediatric studies evaluating the association
between obesity and migraine
Many studies have been performed on adults in order to
evaluate the association between obesity and migraine,
on the contrary, only few papers suggesting an association
between obesity and migraine in the pediatric population
have been published (Table 1). The first study, that spe-
cifically examined this relationship, was conducted in
2008 by Pinhas-Hamiel et al. In this study were evaluated
273 children and adolescents and was found an associ-
ation between migraine and obesity according to the evi-
dence that the prevalence of episodic migraine was of
2.5% in normal weight children, of 4.4% in over-weight
children and 8.9% in obese children [12].
An increase in the frequency of migraine in obese chil-
dren compared with normal-weight children was also
underlined by Kinik et al., who investigated even the influ-
ence of obesity on the severity of migraine in 124 children.
The number and the duration of attacks, pain severity and
associated symptoms were compared between obese, over-
weight and normal weight patients. The results highlighted
no difference in pain severity and migraine duration
among groups, but more frequent attacks in obese than in
the overweight and normal weight patients were observed,
with a positive correlation with BMI [11].
The relationship between migraine and lifestyle factors
was examined by Robberstad et al. in a group of 5847 ado-
lescents. Results highlighted that the risk of migraine was
60% greater in those adolescents who were overweight or
obese. The authors suggested that the intervention on life-
style factors could be a therapeutic strategy [66].
These data were confirmed by Ravid et al., who
showed a higher prevalence of obesity, compared with
the general population, in a group of 181 children with
headaches. This paper evaluated the association between
obesity and generally headache and also the association
between obesity and migraine specifically. The results
showed that migraine was more prevalent in obese and
overweight patients compared with normal weight
patients. Therefore the odds of migraine were almost 2,5
fold greater in those who were overweight compared
with those of normal weight and 3–5 fold greater in
overweight and obese females [67].
In 2012 Pakalnis et al., who retrospectively evaluated
925 children with headache, did not show increased inci-
dence of overweight in children with chronic migraine.
Specifically no significant differences were noted in the
percentage of obese patients with episodic migraine or
obese with chronic migraine compared with data from
general obese population [68].
Conclusions
Pediatric studies analyzed in this review confirm that
migraine and obesity represent two major public health
problems and research is consistent in supporting higher
frequency and severity of headache attacks among obese
children with migraine than in lean controls.
Adult studies show an associations between obesity
and migraine, influenced by age, gender, and lifestyle
factors; in pediatric population there is a recurring cor-
relation too, relatively to the increased frequency and
intensity of migraine attacks in both sexes, and increased
headache episodes in girls.
Studies evaluating the prevalence of overweight in
migraineurs children underline a higher prevalence of
obesity in these subjects than in the general population.
However, the link between migraine and obesity is
complex and still unclear, as the two conditions share
some pathogenic determinants and may influence one
another.
The two chronic diseases show a multifactorial etiology:
genetic factors, inflammatory mediators and common life-
style factors. A dysregulation of the hypothalamic neuro-
peptides involved in migraine can induce an alteration in
feeding regulation. On the other hand, adipokines pro-
ducted by hypertrophic adipose tissue create a systemic
chronic inflammation that may contribute to the neuro-
genic inflammation of migraine: this can explain the
higher frequency and severity of migraine attacks in over-
weight and obese children compared to lean controls.
Obesity and its related complications, such as insulin-
resistance, are risk factors for chronic migraine: this is
highlighted by the evidence that an improvement of
metabolic control in obese subjects, through BMI cor-
rection, may reduce frequency of migraine attacks.
In conclusion, the link between obesity and migraine
is complex and involves both central and peripheral
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pathways, but obesity and migraine are also both influ-
enced by sedentary lifestyle factors.
These evidences have important clinical implications:
body weight management could be relevant for preven-
tion of chronic migraine and represents an alternative
treatment option.
In sight of this, it is crucial, in pediatric migraineurs
obese patients treat these children precociously with a
behavioral therapy targeted to restore the ideal body
weight, in order to reduce the frequency of migraine
attacks, the use of analgesic therapies and the risk of pro-
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